Scarica l'app Stockscreener
5.28
1.86%
-0.10
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ARDX Giù?
Forum
Previsione
Ardelyx Inc Borsa (ARDX) Ultime notizie
Lobbying Update: $20,000 of ARDELYX INC lobbying was just disclosed - Quiver Quantitative
ARDX Edges Up After Hours On IBSRELA Momentum And Profitability ‘Right Around The Corner’ - Stocktwits
ARDX Stock Jumps Over 5% Overnight As Director Loads Up In Vote Of Confidence For Flagship Constipation Drug - Stocktwits
Ardelyx (NASDAQ: ARDX) draws $50M Term F loan maturing in 2030 - Stock Titan
Ardelyx: The Market Is Right To Discount This Revenue Growth - Seeking Alpha
Price to book forward of Ardelyx, Inc. – NASDAQ:ARDX - TradingView
Price to sales forward of Ardelyx, Inc. – NASDAQ:ARDX - TradingView
Price to earnings forward of Ardelyx, Inc. – TRADEGATE:41X - TradingView
Ardelyx, Inc.'s (NASDAQ:ARDX) Shift From Loss To Profit - 富途牛牛
Ardelyx (ARDX) Faces New Medicare Rules For Xphozah After Court Ruling - simplywall.st
ARDX Stock Is Down Pre-Market After Q4 Earnings Miss, So Why Did This Firm Just Hike Price Target By 80%? - Stocktwits
Ardelyx stock decline attributed to setback in Xphozah appeal - MSN
ARDX Stock Tumbles As Xphozah Loses Final Medicare Reimbursement Battle - TradingView
Ardelyx (ARDX) Faces Appeal Setback but Maintains Buy Rating - GuruFocus
Jefferies Maintains Ardelyx(ARDX.US) With Buy Rating, Maintains Target Price $15 - Moomoo
Ardelyx falls after setback in Xphozah appeal (ARDX:NASDAQ) - Seeking Alpha
Ardelyx Loses Appeal of HHS Reclassification of Kidney Drug - Bloomberg Law News
Ardelyx Inc (ARDX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Ardelyx stock trades down as mixed technical signals cap upside potential - Traders Union
ARDX Forecast — Price Target — Prediction for 2027 - TradingView
Ardelyx, Inc. Actuals & Estimates (NASDAQ:ARDX) - TradingView
Ardelyx, Inc. Actuals & Estimates (FWB:41X) - TradingView
41X Forecast — Price Target — Prediction for 2027 - TradingView
Is Ladenburg’s IBSRELA Focus Quietly Reframing Ardelyx’s (ARDX) Risk‑Reward Story? - simplywall.st
Aquestive Therapeutics (AQST) Moves 6.6% Higher: Will This Strength Last? - Yahoo! Finance Canada
Ardelyx Inc (ARDX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Ardelyx Stock Up 70%: What to Know About This $490,000 Insider Transaction - The Globe and Mail
What’s Fueling Optimism Around Ardelyx, Inc. (ARDX)’s Sales and Pipeline? - Yahoo Finance
Ardelyx Inc (ARDX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Form 4 Ardelyx Inc For: 22 June By Investing.com - Investing.com Australia
Ardelyx chief patient officer sells $490k in stock By Investing.com - Investing.com Australia
Ardelyx chief patient officer sells $490k in stock - Investing.com
Ardelyx Insider Sold Shares Worth $490,487, According to a Recent SEC Filing - marketscreener.com
Ardelyx (ARDX) Chief Patient Officer sells shares, exercises 31,000 options - Stock Titan
5 Best Low Priced Stocks to Get Rich in 2026 - Insider Monkey
Ardelyx (ARDX) director granted RSUs and 39,715-share stock option - Stock Titan
Laura A. Williams proposes sale of 31,000 shares (ARDX) - Stock Titan
Ardelyx (ARDX) director receives 26,455 RSUs and 39,715-share option - Stock Titan
Equity grants to Ardelyx (ARDX) director under compensation program - Stock Titan
Ardelyx (ARDX) director Cadoret-Manier receives RSU and option grants - Stock Titan
Ardelyx (ARDX) director receives RSUs and stock options as compensation - Stock Titan
2.64%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):